Cardiovascular Risk in Hypertension - Can We Ask for More?: Focus on Aliskiren

By Volpe Massimo  

High Blood Pressure & Cardiovascular Prevention, Vol. 15, Iss. 4, 2008-01 ,pp. : 255-268

Adis International

Access to resources Recommend Favorite

Lead and Hypertension: Could a Chelator be the Antihypertensive of Choice?

By Salama Mohamed  

High Blood Pressure & Cardiovascular Prevention, Vol. 16, Iss. 3, 2009-09 ,pp. : 83-85

Adis International

Access to resources Recommend Favorite

β-Blockers and Diuretics in the Treatment of Hypertension: `A Friendly Fire?'

By Volpe Massimo  

High Blood Pressure & Cardiovascular Prevention, Vol. 15, Iss. 3, 2008-01 ,pp. : 109-111

Adis International

Access to resources Recommend Favorite

Is Endothelial Dysfunction a Measurable Endpoint in Hypertension?

By Taddei S.   Virdis A.   Ghiadoni L.   Versari D.   Salvetti A.  

High Blood Pressure & Cardiovascular Prevention, Vol. 10, Iss. 1, 2003-01 ,pp. : 19-25

Adis International

Access to resources Recommend Favorite

How useful are hypertension guidelines for diabetes?

By Nilsson Peter M  

Diabetes Management, Vol. 3, Iss. 2, 2013-03 ,pp. : 115-121

Future Medicine

Access to resources Recommend Favorite